Entrada Therapeutics (TRDA) Profit After Tax (2020 - 2026)

Entrada Therapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$406000.0 for Q1 2026.

• In Q1 2026, Profit After Tax rose 97.66% year-over-year to -$406000.0; the TTM figure through Mar 2026 stood at -$143.9 million (down 798.79% YoY), while the FY2025 annual figure was -$143.1 million, down 318.78% from the prior year.
• Profit After Tax for Q1 2026 stood at -$406000.0, up from -$143.7 million in the prior quarter.
• The five-year high for Profit After Tax was $67.9 million in Q4 2022, with the low at -$143.7 million in Q4 2025.
• The 5-year median for Profit After Tax is -$441000.0 (2024), against an average of -$12.1 million.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax soared 468.02% in 2022, then tumbled 123995.69% in 2025.
• Entrada Therapeutics' Profit After Tax stood at $67.9 million in 2022, then plunged by 116.35% to -$11.1 million in 2023, then soared by 101.04% to $116000.0 in 2024, then sank by 123995.69% to -$143.7 million in 2025, then surged by 99.72% to -$406000.0 in 2026.
• Business Quant data shows TRDA's Profit After Tax at -$406000.0 in Q1 2026, -$143.7 million in Q4 2025, and $221000.0 in Q3 2025.